PeerView Family Medicine & General Practice CME/CNE/CPE Audio Podcast

PeerView (PVI) is a leading provider of high-quality, innovative continuing education (CME/CE/CPE and MOC) for clinicians and their interprofessional teams. Combining evidence-based medicine and instructional expertise, PeerView activities improve the knowledge, skills, and strategies that support clinical performance and patient outcomes. PeerView makes its educational programming and expert-led presentations and symposia available through its network of popular podcast channels to support specific specialties and conditions. Each episode includes a link to request CME/CE credit for participation. PeerView is solely responsible for the selection of topics, the preparation of editorial content, and the distribution of all materials it publishes.

http://ww2.peerview.com

subscribe
share





Jonathan I. Silverberg, MD, PhD, MPH - Test Your Knowledge of New and Emerging Therapies for Moderate to Severe Atopic Dermatitis: Latest Evidence and Clinical Potential


Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.


share







 2021-10-02  27m